Citation: Jia Deng, Jianbin Shi, Dan Li, Xue Jiao, Jinrui Liu, Haowen Tian, Na Liu, Cong Luo, Ken-ichiro Kamei, Chutong Tian. Cancer-targeting drug conjugates drives a new era in precise cancer treatment[J]. Chinese Chemical Letters, ;2026, 37(2): 110960. doi: 10.1016/j.cclet.2025.110960 shu

Cancer-targeting drug conjugates drives a new era in precise cancer treatment

Jia Deng ^{a, 1} ,
Jianbin Shi ^{a, 1} ,
Dan Li ^{b, 1} ,
Xue Jiao ^c ,
Jinrui Liu ^a ,
Haowen Tian ^a ,
Na Liu ^a ,
Cong Luo ^{a, d} ,
Ken-ichiro Kamei ^{a, d, e, f, g, h} ,
Chutong Tian ^{a, d, *,}

a.
Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China
b.
Department of Pharmacy, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing 400038, China
c.
Department of Respiratory Disease, The First Affiliated Hospital, Jinzhou Medical University, Jinzhou 121000, China
d.
Joint International Research Laboratory of Intelligent Drug Delivery Systems, Ministry of Education, Shenyang 110016, China
e.
Institute for Integrated Cell-Material Sciences (WPI-iCeMS), Kyoto University, Kyoto 606-8501, Japan
f.
Program of Biology, Division of Science, New York University Abu Dhabi, Abu Dhabi, United Arab Emirates
g.
Program of Bioengineering, Division of Engineering, New York University Abu Dhabi, Abu Dhabi, United Arab Emirates
h.
Department of Biomedical Engineering, Tandon School of Engineering, New York University, MetroTech, Brooklyn, NY 11201, United States

tianct_spu@126.com

Received Date: 19 November 2024
Revised Date: 12 February 2025
Accepted Date: 14 February 2025
Available Online: 15 February 2025

Figures(6)

Cancer is the second leading cause of death globally. Its treatment remains a major challenge due to the disease's complexity, heterogeneity, and adaptive nature. Among the array of available treatments, targeted therapy emerges as a paramount approach to address this substantial unmet clinical need, owing to its precise tumor targeting capabilities and potential for mitigating tumor progression risks. Drug conjugates are in high demand for targeted therapy due to their unique ligand specificity and potent cytotoxicity, thereby significantly enhancing therapeutic efficacy and reducing the incidence of adverse effects. Therefore, as a burgeoning field in biomedical research, it is timely to outline the latest advances in drug conjugates-driven cancer treatment. Herein, we aim to present the emerging breakthroughs in this exciting field at the intersection of target ligands, linkers, payloads, and cancer treatments. This review focuses on several drug conjugates-related strategies, including antibody-drug conjugates (ADCs), peptide-drug conjugates (PDCs), small molecule-drug conjugates (SMDCs), aptamer-drug conjugates (ApDCs) and radionuclide-drug conjugates (RDCs). Finally, we discuss the fundamentals behind drug conjugate-based anticancer therapeutics, along with their inherent advantages and associated challenges, as well as recent research advances.
- Drug conjugates,
- Antibody-drug conjugates,
- Peptide-drug conjugates,
- Small molecule-drug conjugates,
- Targeted therapy,
- Drug discovery,
- Clinical application
1. [1]
  H. Sung, J. Ferlay, R.L. Siegel, et al., CA Cancer J. Clin. 71 (2021) 209–249.
2. [2]
  F. Peyraud, C. Allenet, M. Gross-Goupil, et al., Cancer Treat. Rev. 90 (2020) 102087. doi: 10.1016/j.ctrv.2020.102087
3. [3]
  S. Kumari, S. Mukherjee, D. Sinha, et al., Int. J. Mol. Sci. 21 (2020) 8151. doi: 10.3390/ijms21218151
4. [4]
  C. Li, X. You, X. Xu, et al., Adv. Sci. 9 (2022) e2104134. doi: 10.1002/advs.202104134
5. [5]
  S.Y. Yi, M.Z. Wei, L. Zhao, Crit. Rev. Oncol. Hematol. 196 (2024) 104313. doi: 10.1016/j.critrevonc.2024.104313
6. [6]
  X. Zhu, J. Wu, W. Shan, et al., Angew. Chem. Int. Ed. 55 (2016) 3309–3312. doi: 10.1002/anie.201509183
7. [7]
  N. Bertrand, J. Wu, X. Xu, et al., Adv. Drug Deliv. Rev. 66 (2014) 2–25. doi: 10.1016/j.addr.2013.11.009
8. [8]
  Z. Zhang, R. Sun, C. Bian, et al., Chin. Chem. Lett. 36 (2025) 109784. doi: 10.1016/j.cclet.2024.109784
9. [9]
  B. Hu, L. Zhong, Y. Weng, et al., Signal Transduct. Target. Ther. 5 (2020) 101. doi: 10.1038/s41392-020-0207-x
10. [10]
  L. Zhou, Y. Lu, W. Liu, et al., Exp. Hematol. Oncol. 13 (2024) 26. doi: 10.1186/s40164-024-00493-8
11. [11]
  K. Strebhardt, A. Ullrich, Nat. Rev. Cancer 8 (2008) 473–480. doi: 10.1038/nrc2394
12. [12]
  Z. Fu, S. Li, S. Han, et al., Signal Transduct Target. Ther. 7 (2022) 93. doi: 10.1038/s41392-022-00947-7
13. [13]
  K. Tsuchikama, Y. Anami, S.Y.Y. Ha, C.M. Yamazaki, Nat. Rev. Clin. Oncol. 21 (2024) 203–223. doi: 10.1038/s41571-023-00850-2
14. [14]
  L. Gong, H. Zhao, Y. Liu, et al., Acta Pharm. Sin. B 13 (2023) 3659–3677. doi: 10.1016/j.apsb.2023.02.013
15. [15]
  C. Fu, L. Yu, Y. Miao, et al., Acta Pharm. Sin. B 13 (2023) 498–516. doi: 10.1016/j.apsb.2022.07.020
16. [16]
  A. Juzeniene, V.Y. Stenberg, Ø. S. Bruland, R.H. Larsen, Cancers 13 (2021) 779. doi: 10.3390/cancers13040779
17. [17]
  R. Eychenne, C. Bouvry, M. Bourgeois, et al., Molecules 25 (2020) 4012. doi: 10.3390/molecules25174012
18. [18]
  D.Y. Ruan, H.X. Wu, Q. Meng, R.H. Xu, Cancer Commun. 44 (2024) 3–22. doi: 10.1002/cac2.12517
19. [19]
  J.G. Salfeld, Nat. Biotechnol. 25 (2007) 1369–1372. doi: 10.1038/nbt1207-1369
20. [20]
  M. De Cecco, D.N. Galbraith, L.L. McDermott, Expert Opin. Biol. Ther. 21 (2021) 841–847. doi: 10.1080/14712598.2021.1880562
21. [21]
  L. Qian, X. Lin, X. Gao, et al., Chem. Rev. 123 (2023) 7782–7853. doi: 10.1021/acs.chemrev.2c00915
22. [22]
  M.S. Dennis, H. Jin, D. Dugger, et al., Cancer Res. 67 (2007) 254–261. doi: 10.1158/0008-5472.CAN-06-2531
23. [23]
  Y.S. Zhu, K. Tang, J. Lv, Trends Pharmacol. Sci. 42 (2021) 857–869. doi: 10.1016/j.tips.2021.07.001
24. [24]
  J. Xie, Y. Bi, H. Zhang, et al., Front. Pharmacol. 11 (2020) 697. doi: 10.3389/fphar.2020.00697
25. [25]
  M.B. Hock, K.E. Thudium, M. Carrasco-Triguero, N.F. Schwabe, AAPS J. 17 (2015) 35–43. doi: 10.1208/s12248-014-9684-6
26. [26]
  M.A. Firer, G. Gellerman, J. Hematol. Oncol. 5 (2012) 70. doi: 10.1186/1756-8722-5-70
27. [27]
  N. Vale, D. Duarte, S. Silva, et al., Pharmacol. Res. 162 (2020) 105231. doi: 10.1016/j.phrs.2020.105231
28. [28]
  S. Dissanayake, W.A. Denny, S. Gamage, V. Sarojini, J. Control. Release 250 (2017) 62–76. doi: 10.1016/j.jconrel.2017.02.006
29. [29]
  L. Ge, X. You, K. Huang, et al., Biomater. Sci. 6 (2018) 125–135. doi: 10.1039/C7BM00776K
30. [30]
  X. Sun, H. Li, Z. Chen, et al., Nucleic Acids Res. 53 (2025) D1476–D1485. doi: 10.1093/nar/gkae859
31. [31]
  J. Zhou, N. Meng, L. Lu, et al., J. Control. Release 369 (2024) 722–733. doi: 10.1016/j.jconrel.2024.04.011
32. [32]
  J. Pan, Y. Lai, S. Zhang, et al., Adv. Mater. 35 (2023) e2305798. doi: 10.1002/adma.202305798
33. [33]
  Y. Cao, X. Ge, Y. Wei, et al., Chin. Chem. Lett. 35 (2024) 108672. doi: 10.1016/j.cclet.2023.108672
34. [34]
  V. Akbari, C.P. Chou, D. Abedi, Biochim. Biophys. Acta. Rev. Cancer 1874 (2020) 188448. doi: 10.1016/j.bbcan.2020.188448
35. [35]
  T. Todorovski, D. Kalafatovic, D. Andreu, Pharmaceutics 15 (2023) 357. doi: 10.3390/pharmaceutics15020357
36. [36]
  D.A. Mendonça, M. Bakker, C. Cruz-Oliveira, et al., Bioconjug. Chem. 32 (2021) 1067–1077. doi: 10.1021/acs.bioconjchem.1c00123
37. [37]
  T. Todorovski, D.A. Mendonça, L.O. Fernandes-Siqueira, et al., Pharmaceutics 14 (2022) 738. doi: 10.3390/pharmaceutics14040738
38. [38]
  N. Kaur, P. Popli, N. Tiwary, R. Swami, J. Control. Release 355 (2023) 417–433. doi: 10.1016/j.jconrel.2023.01.032
39. [39]
  M. Srinivasarao, C.V. Galliford, P.S. Low, Nat. Rev. Drug Discov. 14 (2015) 203–219. doi: 10.1038/nrd4519
40. [40]
  C. Zhuang, X. Guan, H. Ma, et al., Eur. J. Med. Chem. 163 (2019) 883–895. doi: 10.1016/j.ejmech.2018.12.035
41. [41]
  Q. Chen, Z. Wu, H. Zhu, et al., J. Med. Chem. 67 (2024) 19586–19611. doi: 10.1021/acs.jmedchem.4c01910
42. [42]
  C.F. Lo, T.Y. Chiu, Y.T. Liu, et al., J. Med. Chem. 65 (2022) 12802–12824. doi: 10.1021/acs.jmedchem.2c00631
43. [43]
  X. Wang, J. Zhang, K. Zheng, et al., J. Pharm. Anal. 13 (2023) 776–787. doi: 10.1016/j.jpha.2023.02.010
44. [44]
  J. He, Q. Duan, C. Ran, et al., Acta Pharm. Sin. B 13 (2023) 1358–1370. doi: 10.1016/j.apsb.2023.01.017
45. [45]
  S. He, Y. Du, H. Tao, H. Duan, Int. J. Biol. Macromol. 238 (2023) 124173. doi: 10.1016/j.ijbiomac.2023.124173
46. [46]
  R. Thevendran, S. Sarah, T.H. Tang, M. Citartan, J. Control. Release 323 (2020) 530–548. doi: 10.1016/j.jconrel.2020.04.051
47. [47]
  C. Yang, Y. Jiang, S.H. Hao, et al., J. Mater. Chem. B 10 (2021) 20–33.
48. [48]
  Y. Liu, Y. Hu, Y. Tan, et al., Chin. Chem. Lett. 36 (2025) 110289. doi: 10.1016/j.cclet.2024.110289
49. [49]
  V. Bagalkot, O.C. Farokhzad, R. Langer, S. Jon, Angew. Chem. Int. Ed. 45 (2006) 8149–8152. doi: 10.1002/anie.200602251
50. [50]
  Y. Hu, J. Duan, Q. Zhan, et al., PLoS One 7 (2012) e31970. doi: 10.1371/journal.pone.0031970
51. [51]
  Z. Liu, J.H. Duan, Y.M. Song, et al., J. Transl. Med. 10 (2012) 148. doi: 10.1186/1479-5876-10-148
52. [52]
  Z. Su, D. Xiao, F. Xie, et al., Acta Pharm. Sin. B 11 (2021) 3889–3907. doi: 10.1016/j.apsb.2021.03.042
53. [53]
  S. Kumari, S. Raj, M.A. Babu, et al., Arch. Pharm. Res. 47 (2024) 40–65. doi: 10.1007/s12272-023-01479-6
54. [54]
  M. Alas, A. Saghaeidehkordi, K. Kaur, J. Med. Chem. 64 (2021) 216–232. doi: 10.1021/acs.jmedchem.0c01530
55. [55]
  H. Wang, L. Wang, Y. Gao, Y. Ding, Chin. Chem. Lett. 32 (2021) 1041–1045. doi: 10.1016/j.cclet.2020.08.044
56. [56]
  N. Dan, S. Setua, V.K. Kashyap, et al., Pharmaceuticals 11 (2018) 32. doi: 10.3390/ph11020032
57. [57]
  F. Bryden, C. Martin, S. Letast, et al., Org. Biomol. Chem. 16 (2018) 1882–1889. doi: 10.1039/C7OB02780J
58. [58]
  Q. Song, X. Chuan, B. Chen, et al., Drug Deliv. 23 (2016) 1734–1746.
59. [59]
  S. Jaracz, J. Chen, L.V. Kuznetsova, I. Ojima, Bioorg. Med. Chem. 13 (2005) 5043–5054. doi: 10.1016/j.bmc.2005.04.084
60. [60]
  X. Lin, L. Wang, L. Zhao, et al., Food Funct. 11 (2020) 4146–4159. doi: 10.1039/D0FO00260G
61. [61]
  G. Wu, Y.Z. Fang, S. Yang, et al., J. Nutr. 134 (2004) 489–492. doi: 10.1093/jn/134.3.489
62. [62]
  J.P.M. António, J.I. Carvalho, A.S. André, et al., Angew. Chem. Int. Ed. 60 (2021) 25914–25921. doi: 10.1002/anie.202109835
63. [63]
  L. Meng, K. Sefah, M.B. O'Donoghue, et al., PLoS One 5 (2010) e14018. doi: 10.1371/journal.pone.0014018
64. [64]
  M. Walles, A. Connor, D. Hainzl, Curr. Top. Med. Chem. 17 (2017) 3463–3475.
65. [65]
  Z.X. Phuna, P.A. Kumar, E. Haroun, et al., Life Sci. 347 (2024) 122676. doi: 10.1016/j.lfs.2024.122676
66. [66]
  P. Khongorzul, C.J. Ling, F.U. Khan, et al., Mol. Cancer Res. 18 (2020) 3–19. doi: 10.1158/1541-7786.MCR-19-0582
67. [67]
  L. Conilh, L. Sadilkova, W. Viricel, C. Dumontet, J. Hematol. Oncol. 16 (2023) 3. doi: 10.1186/s13045-022-01397-y
68. [68]
  Y.T. Tai, P.A. Mayes, C. Acharya, et al., Blood 123 (2014) 3128–3138. doi: 10.1182/blood-2013-10-535088
69. [69]
  A. Gazzah, P.L. Bedard, C. Hierro, et al., Ann. Oncol. 33 (2022) 416–425. doi: 10.1016/j.annonc.2021.12.012
70. [70]
  H. Suzuki, S. Nagase, C. Saito, et al., Mol. Cancer Ther. 23 (2024) 257–271.
71. [71]
  X. Zhang, D. Li, J. Huang, et al., J. Mater. Chem. B 7 (2019) 251–264. doi: 10.1039/C8TB02474J
72. [72]
  K.C. Nicolaou, S. Rigol, Acc. Chem. Res. 52 (2019) 127–139. doi: 10.1021/acs.accounts.8b00537
73. [73]
  M.J. McPherson, A.D. Hobson, A. Hernandez Jr., et al., Sci. Transl. Med. 16 (2024) eadd8936. doi: 10.1126/scitranslmed.add8936
74. [74]
  T. Wieland, H. Faulstich, Experientia 47 (1991) 1186–1193. doi: 10.1007/BF01918382
75. [75]
  P. Pal, P. Zhang, S.K. Poddar, G. Zheng, Expert Opin. Ther. Pat. 32 (2022) 1003–1026. doi: 10.1080/13543776.2022.2116311
76. [76]
  K. Holen, L.B. Saltz, E. Hollywood, et al., Invest. New Drugs 26 (2008) 45–51. doi: 10.1007/s10637-007-9083-2
77. [77]
  S. Gervasoni, I. Öztürk, C. Guccione, et al., J. Chem. Inf. Model. 63 (2023) 4924–4933. doi: 10.1021/acs.jcim.3c00712
78. [78]
  R. Lengacher, A. Marlin, D. Śmiłowicz, E. Boros, Chem. Soc. Rev. 51 (2022) 7715–7731. doi: 10.1039/D2CS00407K
79. [79]
  T.J. Wadas, E.H. Wong, G.R. Weisman, C.J. Anderson, Chem. Rev. 110 (2010) 2858–2902. doi: 10.1021/cr900325h
80. [80]
  S. Sheikhbahaei, M.S. Sadaghiani, S.P. Rowe, L.B. Solnes, AJR Am. J. Roentgenol. 217 (2021) 495–506. doi: 10.2214/AJR.20.23349
81. [81]
  N. Vahidfar, S. Farzanehfar, M. Abbasi, et al., Cancers 14 (2022) 1914. doi: 10.3390/cancers14081914
82. [82]
  H. Maecker, V. Jonnalagadda, S. Bhakta, et al., mAbs 15 (2023) 2229101. doi: 10.1080/19420862.2023.2229101
83. [83]
  J.K. McGavin, C.M. Spencer, Drugs 61 (2001) 1317–1322. doi: 10.2165/00003495-200161090-00007
84. [84]
  S.H. Petersdorf, K.J. Kopecky, M. Slovak, et al., Blood 121 (2013) 4854–4860. doi: 10.1182/blood-2013-01-466706
85. [85]
  J. Lambert, C. Pautas, C. Terré, et al., Haematologica 104 (2019) 113–119. doi: 10.3324/haematol.2018.188888
86. [86]
  H.M. Kantarjian, D.J. DeAngelo, M. Stelljes, et al., N. Engl. J. Med. 375 (2016) 740–753. doi: 10.1056/NEJMoa1509277
87. [87]
  A.D. Ricart, Clin. Cancer Res. 17 (2011) 6417–6427. doi: 10.1158/1078-0432.CCR-11-0486
88. [88]
  N. Zein, A.M. Sinha, W.J. McGahren, G.A. Ellestad, Science 240 (1988) 1198–1201. doi: 10.1126/science.3240341
89. [89]
  S. Girish, M. Gupta, B. Wang, et al., Cancer Chemother. Pharmacol. 69 (2012) 1229–1240. doi: 10.1007/s00280-011-1817-3
90. [90]
  S. Verma, D. Miles, L. Gianni, et al., N. Engl. J. Med. 367 (2012) 1783–1791. doi: 10.1056/NEJMoa1209124
91. [91]
  N.W. van de Donk, E. Dhimolea, mAbs 4 (2012) 458–465. doi: 10.4161/mabs.20230
92. [92]
  J.A. Francisco, C.G. Cerveny, D.L. Meyer, et al., Blood 102 (2003) 1458–1465. doi: 10.1182/blood-2003-01-0039
93. [93]
  A. Younes, A.K. Gopal, S.E. Smith, et al., J. Clin. Oncol. 30 (2012) 2183–2189. doi: 10.1200/JCO.2011.38.0410
94. [94]
  B. Pro, R. Advani, P. Brice, et al., J. Clin. Oncol. 30 (2012) 2190–2196. doi: 10.1200/JCO.2011.38.0402
95. [95]
  D. Dornan, F. Bennett, Y. Chen, et al., Blood 114 (2009) 2721–2729.
96. [96]
  L.H. Sehn, A.F. Herrera, C.R. Flowers, et al., J. Clin. Oncol. 38 (2020) 155–165.
97. [97]
  E.Y. Yu, D.P. Petrylak, P.H. O'Donnell, et al., Lancet Oncol. 22 (2021) 872–882. doi: 10.1016/S1470-2045(21)00094-2
98. [98]
  Y. Ogitani, K. Hagihara, M. Oitate, et al., Cancer Sci. 107 (2016) 1039–1046. doi: 10.1111/cas.12966
99. [99]
  S. Modi, C. Saura, T. Yamashita, et al., N. Engl. J. Med. 382 (2020) 610–621. doi: 10.1056/NEJMoa1914510
100. [100]
  K. Shitara, Y.J. Bang, S. Iwasa, et al., N. Engl. J. Med. 382 (2020) 2419–2430. doi: 10.1056/NEJMoa2004413
101. [101]
  U. Hennrich, K. Kopka, Pharmaceuticals 12 (2019) 114. doi: 10.3390/ph12030114
102. [102]
  S. Dhillon, Drugs 81 (2021) 963–969. doi: 10.1007/s40265-021-01522-0
103. [103]
  U. Hennrich, M. Eder, Pharmaceuticals 15 (2022) 1292. doi: 10.3390/ph15101292
104. [104]
  I. Vergote, C.P. Leamon, Ther. Adv. Med. Oncol. 7 (2015) 206–218. doi: 10.1177/1758834015584763
105. [105]
  J.Y. Park, Y.L. Cho, J.R. Chae, et al., Mol. Ther. Nucleic Acids 12 (2018) 543–553. doi: 10.1016/j.omtn.2018.06.003
106. [106]
  S. Cavdarli, S. Groux-Degroote, P. Delannoy, Biomolecules 9 (2019) 311. doi: 10.3390/biom9080311
107. [107]
  D.V. Kalinovsky, I.V. Kholodenko, A.V. Kibardin, et al., Int. J. Mol. Sci. 24 (2023) 1239. doi: 10.3390/ijms24021239
108. [108]
  I. Nessler, E. Khera, S. Vance, et al., Cancer Res. 80 (2020) 1268–1278. doi: 10.1158/0008-5472.CAN-19-2295
109. [109]
  L. Jolivet, I. Ait Mohamed Amar, C. Horiot, et al., Pharmaceutics 14 (2022) 114063.
110. [110]
  A.S. André, J.N.R. Dias, S. Aguiar, et al., Sci. Rep. 13 (2023) 4837. doi: 10.1038/s41598-023-31568-x
111. [111]
  L. He, L. Wang, Z. Wang, et al., J. Med. Chem. 64 (2021) 15716–15726. doi: 10.1021/acs.jmedchem.1c00961
112. [112]
  S.Y.Y. Ha, Y. Anami, C.M. Yamazaki, et al., Mol. Cancer Ther. 21 (2022) 1449–1461. doi: 10.1158/1535-7163.MCT-22-0362
113. [113]
  D.A. Rose, J.W. Treacy, Z.J. Yang, et al., J. Am. Chem. Soc. 144 (2022) 6050–6058. doi: 10.1021/jacs.2c01136
114. [114]
  D. Wei, Y. Mao, H. Wang, et al., Chin. Chem. Lett. 34 (2023) 108091. doi: 10.1016/j.cclet.2022.108091
115. [115]
  Z. Ma, H. He, F. Sun, et al., J. Cancer Res. Clin. Oncol. 143 (2017) 1929–1940. doi: 10.1007/s00432-017-2436-0
116. [116]
  F. Sun, Y. Wang, X. Luo, et al., Cancer Res. 79 (2019) 3395–3405.
117. [117]
  K. Johnson, J.C. Delaney, T. Guillard, et al., PLoS Pathog. 19 (2023) e1011612. doi: 10.1371/journal.ppat.1011612
118. [118]
  C.R. Raetz, C. Whitfield, Annu. Rev. Biochem. 71 (2002) 635–700. doi: 10.1146/annurev.biochem.71.110601.135414
119. [119]
  A. Han, O. Olsen, C. D'Souza, et al., J. Med. Chem. 64 (2021) 11958–11971. doi: 10.1021/acs.jmedchem.1c00541
120. [120]
  D.N. Louis, A. Perry, G. Reifenberger, et al., Acta Neuropathol. 131 (2016) 803–820. doi: 10.1007/s00401-016-1545-1
121. [121]
  E.I. Deryugina, M.A. Bourdon, R.A. Reisfeld, A. Strongin, Cancer Res. 58 (1998) 3743–3750.
122. [122]
  D.V. Hingorani, C.N. Lippert, J.L. Crisp, et al., PLoS One 13 (2018) e0198464. doi: 10.1371/journal.pone.0198464
123. [123]
  D. Hua, L. Tang, W. Wang, et al., Adv. Sci. 8 (2021) 2001960. doi: 10.1002/advs.202001960
124. [124]
  A. Montero, F. Fossella, G. Hortobagyi, V. Valero, Lancet Oncol. 6 (2005) 229–239. doi: 10.1016/S1470-2045(05)70094-2
125. [125]
  G.S. Karagiannis, J.M. Pastoriza, Y. Wang, et al., Sci. Transl. Med. 9 (2017) eaan0026. doi: 10.1126/scitranslmed.aan0026
126. [126]
  C. Li, J. Lang, Y. Wang, et al., Acta Pharm. Sin. B 13 (2023) 3849–3861. doi: 10.1016/j.apsb.2023.03.024
127. [127]
  M.J. Hinner, R.S.B. Aiba, T.J. Jaquin, et al., Clin. Cancer Res. 25 (2019) 5878–5889. doi: 10.1158/1078-0432.CCR-18-3654
128. [128]
  Y. Zeng, X. Liao, Y. Guo, et al., J. Control. Release 366 (2024) 838–848. doi: 10.1016/j.jconrel.2023.12.034
129. [129]
  M. Bocci, A. Zana, L. Principi, et al., J. Control. Release 367 (2024) 779–790. doi: 10.1016/j.jconrel.2024.02.014
130. [130]
  T.U. Amin, R. Emara, A. Pal, et al., J. Med. Chem. 65 (2022) 15473–15486. doi: 10.1021/acs.jmedchem.2c01423
131. [131]
  A. Pal, W. Albusairi, F. Liu, et al., Mol. Pharm. 16 (2019) 3237–3252. doi: 10.1021/acs.molpharmaceut.9b00432
132. [132]
  Y. Zheng, R. Xu, H. Cheng, W. Tai, Mol. Ther. 32 (2024) 1048–1060. doi: 10.1016/j.ymthe.2024.02.020
133. [133]
  T.J. Dougherty, C.J. Gomer, B.W. Henderson, et al., J. Natl. Cancer Inst. 90 (1998) 889–905. doi: 10.1093/jnci/90.12.889
134. [134]
  K. Lu, C. He, W. Lin, J. Am. Chem. Soc. 136 (2014) 16712–16715. doi: 10.1021/ja508679h
135. [135]
  N.M. Idris, M.K. Gnanasammandhan, J. Zhang, et al., Nat. Med. 18 (2012) 1580–1585. doi: 10.1038/nm.2933
136. [136]
  Y. Yang, J. Liu, X. Sun, et al., Nano Res. 9 (2016) 139–148. doi: 10.1007/s12274-015-0898-4
137. [137]
  S. Wilhelm, A.J. Tavares, Q. Dai, et al., Nat. Rev. Mater. 1 (2016) 16014. doi: 10.1038/natrevmats.2016.14
138. [138]
  D. Ling, M.J. Hackett, T. Hyeon, Nat. Mater. 13 (2014) 122–124. doi: 10.1038/nmat3860
139. [139]
  Y. Yang, W. Zhu, L. Cheng, et al., Biomaterials 246 (2020) 119971. doi: 10.1016/j.biomaterials.2020.119971
140. [140]
  T.P. Szatrowski, C.F. Nathan, Cancer Res. 51 (1991) 794–798.
141. [141]
  P.T. Schumacker, Cancer Cell 10 (2006) 175–176. doi: 10.1016/j.ccr.2006.08.015
142. [142]
  H. Ranji-Burachaloo, P.A. Gurr, D.E. Dunstan, G.G. Qiao, ACS Nano 12 (2018) 11819–11837. doi: 10.1021/acsnano.8b07635
143. [143]
  Z. Zhou, J. Song, R. Tian, et al., Angew. Chem. Int. Ed. 56 (2017) 6492–6496. doi: 10.1002/anie.201701181
144. [144]
  A. Rösler, G.W. Vandermeulen, H.A. Klok, Adv. Drug Deliv. Rev. 53 (2001) 95–108. doi: 10.1016/S0169-409X(01)00222-8
145. [145]
  W. Xuan, Y. Xia, T. Li, et al., J. Am. Chem. Soc. 142 (2020) 937–944. doi: 10.1021/jacs.9b10755
146. [146]
  A. Lee, M.B.A. Djamgoz, Cancer Treat. Rev. 62 (2018) 110–122. doi: 10.1016/j.ctrv.2017.11.003
147. [147]
  J. He, T. Peng, Y. Peng, et al., J. Am. Chem. Soc. 142 (2020) 2699–2703. doi: 10.1021/jacs.9b10510
148. [148]
  N.K. Tafreshi, M.L. Doligalski, C.J. Tichacek, et al., Molecules 24 (2019) 4341. doi: 10.3390/molecules24234341
149. [149]
  T. Langbein, G. Chaussé, R.P. Baum, J. Nucl. Med. 59 (2018) 1172–1173. doi: 10.2967/jnumed.118.214379
150. [150]
  A.P. Bidkar, S. Wang, K.N. Bobba, et al., Clin. Cancer Res. 29 (2023) 1916–1928. doi: 10.1158/1078-0432.CCR-22-3291
151. [151]
  D. Sehlin, X.T. Fang, L. Cato, et al., Nat. Commun. 7 (2016) 10759. doi: 10.1038/ncomms10759
152. [152]
  G. van Dongen, W. Beaino, A.D. Windhorst, et al., J. Nucl. Med. 62 (2021) 438–445. doi: 10.2967/jnumed.119.239558
153. [153]
  T.E. Wuensche, N. Stergiou, I. Mes, et al., Theranostics 12 (2022) 7067–7079. doi: 10.7150/thno.73509
154. [154]
  N. Kamran, P. Kadiyala, M. Saxena, et al., Mol. Ther. 25 (2017) 232–248. doi: 10.1016/j.ymthe.2016.10.003
155. [155]
  S. Nigam, L. McCarl, R. Kumar, et al., Mol. Imaging Biol. 22 (2020) 685–694. doi: 10.1007/s11307-019-01427-1
156. [156]
  A. Foster, S. Nigam, D.S. Tatum, et al., EBioMedicine 71 (2021) 103571. doi: 10.1016/j.ebiom.2021.103571
1. [1]
  Jiawei Zhu , Yucheng Xiong , Xiaoxue Bai , Chenlong Xie , Baichen Xiong , Yao Chen , Haopeng Sun . Small molecule-drug conjugates: Mechanistic insights and strategic design for enhanced cancer therapy. Chinese Chemical Letters, 2025, 36(10): 110799-. doi: 10.1016/j.cclet.2024.110799
2. [2]
  Qijie Gong , Jian Song , Yihui Song , Kai Tang , Panpan Yang , Xiao Wang , Min Zhao , Liang Ouyang , Li Rao , Bin Yu , Peng Zhan , Saiyang Zhang , Xiaojin Zhang . New techniques and strategies in drug discovery (2020–2024 update). Chinese Chemical Letters, 2025, 36(3): 110456-. doi: 10.1016/j.cclet.2024.110456
3. [3]
  Yi Cao , Xiaojiao Ge , Yuanyuan Wei , Lulu He , Aiguo Wu , Juan Li . Tumor microenvironment-activatable neuropeptide-drug conjugates enhanced tumor penetration and inhibition via multiple delivery pathways and calcium deposition. Chinese Chemical Letters, 2024, 35(4): 108672-. doi: 10.1016/j.cclet.2023.108672
4. [4]
  Si Ha , Jiacheng Zhu , Hua Xiang , Guoshun Luo . Hydrophobic tag tethering degrader as a promising paradigm of protein degradation: Past, present and future perspectives. Chinese Chemical Letters, 2024, 35(8): 109192-. doi: 10.1016/j.cclet.2023.109192
5. [5]
  Jian Li , Jinjin Chen , Qi-Long Hu , Zhen Wang , Xiao-Feng Xiong . Recent progress of chemical methods for lysine site-selective modification of peptides and proteins. Chinese Chemical Letters, 2025, 36(5): 110126-. doi: 10.1016/j.cclet.2024.110126
6. [6]
  Jing Feng , Yanhong Liu , Liming Gong , Chenfei Liu , Congcong Xiao , Liqing Chen , Mingji Jin , Zhonggao Gao , Wei Huang , Yubo Li . Recent progress on drug delivery systems of regulating intratumoral bacteria for tumor therapy. Chinese Chemical Letters, 2025, 36(11): 110907-. doi: 10.1016/j.cclet.2025.110907
7. [7]
  Yan Yu , Cailing Gan , Kun Shi , Zhongwu Bei , Yang Yu , Meng Pan , Hanzhi Deng , Zhiyong Qian . Recent advances in drug delivery systems for pulmonary fibrosis therapy. Chinese Chemical Letters, 2026, 37(1): 111596-. doi: 10.1016/j.cclet.2025.111596
8. [8]
  Yiyao Wan , Wen Chen , Yan Yu , Meng Pan , Kun Shi , Zhiyong Qian . Biomaterial-based drug delivery systems for the therapy of malignant pleural effusion. Chinese Chemical Letters, 2026, 37(1): 111513-. doi: 10.1016/j.cclet.2025.111513
9. [9]
  Linghui Zou , Meng Cheng , Kaili Hu , Jianfang Feng , Liangxing Tu . Vesicular drug delivery systems for oral absorption enhancement. Chinese Chemical Letters, 2024, 35(7): 109129-. doi: 10.1016/j.cclet.2023.109129
10. [10]
  Fengjie Liu , Fansu Meng , Zhenjiang Yang , Huan Wang , Yuehong Ren , Yu Cai , Xingwang Zhang . Exosome-biomimetic nanocarriers for oral drug delivery. Chinese Chemical Letters, 2024, 35(9): 109335-. doi: 10.1016/j.cclet.2023.109335
11. [11]
  Ningyue Xu , Jun Wang , Lei Liu , Changyang Gong . Injectable hydrogel-based drug delivery systems for enhancing the efficacy of radiation therapy: A review of recent advances. Chinese Chemical Letters, 2024, 35(8): 109225-. doi: 10.1016/j.cclet.2023.109225
12. [12]
  Yihan Zhou , Duo Gao , Yaying Wang , Li Liang , Qingyu Zhang , Wenwen Han , Jie Wang , Chunliu Zhu , Xinxin Zhang , Yong Gan . Worm-like micelles facilitate the intestinal mucus diffusion and drug accumulation for enhancing colorectal cancer therapy. Chinese Chemical Letters, 2024, 35(6): 108967-. doi: 10.1016/j.cclet.2023.108967
13. [13]
  Chenshi Lin , Chao Teng , Bingbing Li , Wei He . Anti-inflammatory drug-assisted microRNA gene therapy for effectively improving pulmonary hemodynamics. Chinese Chemical Letters, 2025, 36(7): 110450-. doi: 10.1016/j.cclet.2024.110450
14. [14]
  Min Zhang , Ye Chen , Yanan Li , Yifan Zhao , Bai Lv , Jie Cao , Bing Yu , Hailin Cong . Manipulating extracellular matrix to enhance intratumor drug delivery for nanomaterial-based photothermal therapy. Chinese Chemical Letters, 2025, 36(12): 111588-. doi: 10.1016/j.cclet.2025.111588
15. [15]
  Ting Zhang , Deqiang Chen , Ningzhi Zhang , Mingxu Zhang , Qiang Huang , Wei Liu , Ran Gao , Yong Zhang . Self-assembled supramolecular nanofibers integrate pH-responsive drug delivery and antimicrobial for combined cancer therapy. Chinese Chemical Letters, 2026, 37(2): 111117-. doi: 10.1016/j.cclet.2025.111117
16. [16]
  Jiechen Liu , Xiaoguang Li , Ruiyang Xia , Yuqi Wang , Fenghe Zhang , Yongzhi Pang , Qing Li . Efficient suppression of oral squamous cell carcinoma through spatial dimension conversion drug delivery systems-enabled immunomodulatory-photodynamic therapy. Chinese Chemical Letters, 2024, 35(12): 109619-. doi: 10.1016/j.cclet.2024.109619
17. [17]
  Mingrui Zhang , Lingyu Jin , Yuda Zhu , Junfeng Kou , Bo Liu , Jing Chen , Xiaolin Zhong , Xianghua Wu , Junfeng Zhang , Wenxiu Ren . A near-infrared Ⅱ fluorescent dye based on oxanthracene: Real-time imaging of drug-induced acute liver injury and photothermal therapy for tumor. Chinese Chemical Letters, 2025, 36(10): 110772-. doi: 10.1016/j.cclet.2024.110772
18. [18]
  Yujie Li , Ya-Nan Wang , Yin-Gen Luo , Hongcai Yang , Jinrui Ren , Xiao Li . Advances in synthetic biology-based drug delivery systems for disease treatment. Chinese Chemical Letters, 2024, 35(11): 109576-. doi: 10.1016/j.cclet.2024.109576
19. [19]
  Shaoqing Du , Xinyong Liu , Xueping Hu , Peng Zhan . Targeting novel sites represents an effective strategy for combating drug resistance. Chinese Chemical Letters, 2025, 36(1): 110378-. doi: 10.1016/j.cclet.2024.110378
20. [20]
  Shifang Song , Chenyu Wu , Li Zhang , Dezhi Yang , Yang Lu , Zhengzheng Zhou . Unpacking phase transitions in multi-component drug systems: A case study. Chinese Chemical Letters, 2025, 36(7): 110911-. doi: 10.1016/j.cclet.2025.110911

Get Citation

PDF

XML

Metrics

PDF Downloads(0)
Abstract views(19)
HTML views(2)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142